Methods of Diagnosing and Treating Multiple Sclerosis
Argentina
20240100235
Filed on 2024-01-31
20240100235
Filed on 2024-01-31
HIGH-RESOLUTION CEREBROSPINAL FLUID-SUPPRESSED T2*-WEIGHTED MAGNETIC RESONANCE IMAGING OF CORTICAL LESIONS
The Netherlands
20726999.4
Filed on 2021-10-20
20726999.4
Filed on 2021-10-20
HIGH-RESOLUTION CEREBROSPINAL FLUID-SUPPRESSED T2*-WEIGHTED MAGNETIC RESONANCE IMAGING OF CORTICAL LESIONS
Germany
20726999.4
Filed on 2021-10-20
20726999.4
Filed on 2021-10-20
HIGH-RESOLUTION CEREBROSPINAL FLUID-SUPPRESSED T2*-WEIGHTED MAGNETIC RESONANCE IMAGING OF CORTICAL LESIONS
France
20726999.4
Filed on 2021-10-20
20726999.4
Filed on 2021-10-20
HIGH-RESOLUTION CEREBROSPINAL FLUID-SUPPRESSED T2*-WEIGHTED MAGNETIC RESONANCE IMAGING OF CORTICAL LESIONS
United Kingdom
20726999.4
Filed on 2021-10-20
20726999.4
Filed on 2021-10-20
Combination Treatment of Multiple Sclerosis
US Application 63/623,681
Filed on 2024-01-22
Filed on 2024-01-22
BRINCIDOFOVIR FOR TREATMENT OF DISEASES CAUSED BY B-CELLS INFECTED WITH EBV
US Application 63/586,814
Filed on 2023-09-29
Filed on 2023-09-29
SHORT HAIRPIN RNA-MEDIATED INHIBITION OF HERV-K EXPRESSION AND USES THEREOF
US Application 63/680,228
Filed on 2024-08-07
Filed on 2024-08-07
2,4-DIPHENYL-3,4-DIHYDROQUINAZOLINE DERIVATIVES AND RELATED COMPOUNDS AS D2 DOPAMINE RECEPTOR-SELECTIVE ANTAGONISTS
US Application 63/666,563
Filed on 2024-07-01
Filed on 2024-07-01
Sodium Nitrite as a Repurposed Pharmaceutical Agent Wins LES Deals of Distinction Award
The 2009 award winner for this category is a group of licensing agreements for the development of sodium nitrite as a repurposed pharmaceutical agent potentially effective against a number of serious medical conditions. The National Institutes of Health (NIH), supported by four university collaborators, was able complete exclusive license agreements with Hope Pharmaceuticals (for infused delivery) and Aires Pharmaceuticals (for inhaled delivery) to develop new treatments for conditions not well-managed by existing therapies.